Xbrane Biopharma Q4 2023: Navigating muddy waters
Research Update
2024-03-01
07:55
Redeye comments on Xbrane’s year-end report, updates its forecasts following recent developments, and adjusts its valuation for the rights issue which has had large implications on the share price.
FE
Filip Einarsson
Disclosures and disclaimers